Disease Areas:
CoughDevice Types:
VitaloJAKThis review outlined novel therapeutic avenues in the development of drugs targeting refractory chronic cough. Topics included cough hypersensitivity, cough receptors, and molecular targets for new antitussive drugs. An overview of the pivotal COUGH-1 and COUGH-2 trials of gefapixant in patients with refractory chronic cough lasting more than 1 year was provided. The primary efficacy outcome of these trials was 24-hour cough frequency, which was assessed using the Vitalograph VitaloJAK cough monitor.
